Additional information can be found in Helicos' Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC on March 31, 2011 together with its Quarterly Report on Form 10-Q for the second quarter 2011, as filed with the SEC on August 12, 2011. These reports include a discussion regarding the company's need to raise capital, disclosures regarding the company's operational results and liquidity position, and additional disclosures regarding other risks and uncertainties faced by Helicos.About Helicos BioSciences: Helicos BioSciences is focused on innovative sequencing-based genetic analysis technologies. Helicos' proprietary True Single Molecule Sequencing (tSMS(TM)) technology allows the direct measurement of natural DNA without the confounding steps of sample manipulation or nucleic acid amplification. Helicos is committed to commercializing new options for researchers, patients and physicians seeking reliable, cost-efficient nucleic acid sequencing results. For more information, please visit www.helicosbio.com. Forward Looking Statements: This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements herein which are not strictly historical statements, including, without limitation, expressed or implied statements regarding Helicos’ intellectual property portfolio and the expansion thereof and the potential for maximizing the value of Helicos for its stakeholders, management’s strategy, plans and objectives for future operations, and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the costs of, and potential for an adverse outcome from, our existing and any future intellectual property litigation; our ability to obtain, maintain and protect our intellectual property rights; our limited financial resources and substantial doubt about our ability to continue as a going concern; our ability to obtain capital on favorable terms or at all; our ability to retain our remaining personnel or to find adequate replacements, if necessary; and other risks detailed in Helicos’ annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Helicos periodically files with the Securities and Exchange Commission. Helicos does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the publication of this press release, except as required by law.